A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy

PHASE3CompletedINTERVENTIONAL
Enrollment

181

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Essential Hypertension
Interventions
DRUG

Candesartan cilexetil 16mg

Daily oral administration for 8 weeks

DRUG

Amlodipine 10mg, Candesartan cilexetil 16mg

Daily oral administration for 8 weeks

Trial Locations (19)

Unknown

Hallym University Sungsim Hospital, Anyang-si

Inje University Busan Baik Hospital, Busan

Inje University Haeundae Baik Hospital, Busan

Yeungnam University Medical Center, Daegu

Chonnam National University Hospital, Gwangju

Inje University Ilsan Baik Hospital, Ilsan

Inha University Hospital, Incheon

Seoul National University Bundang Hospital, Seongnam-si

Asan Medical Center, Seoul

Ewha Womans University Mokdong Hospital, Seoul

Gangbuk Samsung Hospital, Seoul

Korea University Anam Hospital, Seoul

Korea University Guro Hospital, Seoul

Seoul Medical Center, Seoul

Seoul St. Mary's Hospital Catholic University, Seoul

Soonchunhyang University Hospital, Seoul

Yonsei University Severance Hospital, Seoul

Ajou University Hospital, Suwon

Wonju Severance Christian Hospital, Wŏnju

Sponsors
All Listed Sponsors
lead

HK inno.N Corporation

INDUSTRY